Who
Michael H. Mulroy
Director
Company insider
Files Form 4 as: Director, Lineage Cell Therapeutics; Director, Serina Therapeutics; President and CEO, Asterias Biotherapeutics; EVP, Strat. Affairs & GC, Questcor Pharmaceuticals; Director, Comarco.
In numbers
- Trades disclosed
- 85
- Buys
- 15
- Sells
- 6
- Bought
- $133K
- Sold
- $5.1M
- Companies
- 5
- Companies where not an officer
- 3
- First trade
- 16 Feb 2011
- Last trade
- 1 Jul 2026
- Last filed
- 2 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Jul 2026filed 2 Jul 2026 | LCTX Lineage Cell Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —125,000 at $0.00 | filing |
| 1 Jul 2026filed 2 Jul 2026 | LCTX Lineage Cell Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —125,000 at $0.00 | filing |
| 1 Jul 2025filed 2 Jul 2025 | LCTX Lineage Cell Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 22 Nov 2024filed 25 Nov 2024 | LCTX Lineage Cell TherapeuticsBiotechnology | SEC FORM 4 Bought | $23K40,000 at $0.57 | filing |
| 1 Jul 2024filed 3 Jul 2024 | LCTX Lineage Cell Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 1 Jul 2023filed 3 Jul 2023 | LCTX Lineage Cell Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 1 Jul 2022filed 6 Jul 2022 | LCTX Lineage Cell Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 24 Mar 2022filed 25 Mar 2022 | LCTX Lineage Cell TherapeuticsBiotechnology | SEC FORM 4 Bought | $9,8007,000 at $1.40 | filing |
| 1 Jul 2021filed 1 Jul 2021 | LCTX Lineage Cell Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 18 Jun 2021filed 21 Jun 2021 | LCTX Lineage Cell TherapeuticsBiotechnology | SEC FORM 4 Code M | $54K24,720 at $2.20 | filing |
| 18 Jun 2021filed 21 Jun 2021 | LCTX Lineage Cell Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —24,720 at $0.00 | filing |
| 1 Jul 2020filed 2 Jul 2020 | LCTX Lineage Cell Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 1 Jul 2019filed 3 Jul 2019 | LCTX Lineage Cell Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 11 Mar 2019filed 13 Mar 2019 | SER Serina Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —65,000 at $0.00 | filing |
| 8 Mar 2019filed 15 Mar 2019 | LCTX Lineage Cell TherapeuticsBiotechnology | SEC FORM 4 Code A | —194,271 | filing |
| 1 Mar 2019filed 5 Mar 2019 | Asterias Biotherapeutics | SEC FORM 4 Code A | —252,606 at $0.00 | filing |
| 1 Mar 2019filed 5 Mar 2019 | Asterias Biotherapeutics | SEC FORM 4 Code F | $73K76,588 at $0.95 | filing |
| 27 Aug 2018filed 29 Aug 2018 | Asterias Biotherapeutics | SEC FORM 4 Bought | $4,9943,141 at $1.59 | filing |
| 25 Jul 2018filed 27 Jul 2018 | Asterias Biotherapeutics | SEC FORM 4 Bought | $4,9862,950 at $1.69 | filing |
| 1 Jul 2018filed 3 Jul 2018 | LCTX Lineage Cell Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
News
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Shares Down 1.2% – What's Next?LCTX · dailypolitical.com · 17 Oct 2026
0 headlines in the last 90 days name Michael H. Mulroy; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.
Sectors
Related people
Nobody else traded the same names lately.